京东健康：2025年收入和利润超市场预期，线下药店及AI布局稳步推进-20260309

Investment Rating - The report maintains an "Outperform" rating for JD Health International with a target price of HKD 71.07, while the current price is HKD 49.18 [2]. Core Insights - JD Health International's FY2025 revenue reached RMB 73.4 billion, representing a year-on-year growth of 26.3%, exceeding market expectations. The adjusted net profit was RMB 6.5 billion, up 36.3% year-on-year, with an adjusted net margin of 8.9%, the highest since the company's listing [3][13]. - The company has seen a consistent increase in revenue growth, with Q4 2025 revenue accelerating to RMB 21.0 billion, a 27.5% increase year-on-year, driven by strong performance in drugs, health supplements, and advertising [14]. - The growth in service revenue (3P) outpaced product revenue (1P), with service revenue reaching RMB 12.6 billion, a 34.1% increase year-on-year, indicating enhanced platform monetization capabilities [15]. - The expansion of offline pharmacy stores and the integration of medical insurance payment services into 29 cities are expected to improve service efficiency and enhance online-offline integration [16]. - The introduction of AI products, including "AI Jingyi" for consumers and "JD Zhuoyi" for hospitals, has created a comprehensive matrix that enhances user engagement and satisfaction [17]. Financial Projections - Revenue forecasts for 2026 and 2027 are set at RMB 86.9 billion and RMB 100.1 billion, respectively, with year-on-year growth rates of 18.3% and 15.2% [18]. - Adjusted net profit projections for 2026 and 2027 are RMB 6.5 billion and RMB 7.6 billion, reflecting a modest growth of 0.2% and a more robust 16.4% [18]. - The report anticipates a gross margin of 25.0% in 2026, with a gradual increase to 25.3% by 2027, indicating ongoing operational efficiency improvements [18]. Valuation - The DCF valuation method estimates the company's equity value at HKD 227.4 billion, corresponding to a target price of HKD 71.07 per share, maintaining the "Outperform" rating [19].